Shelly Yang is the Business Development Manager at Energenesis Biomedical Co., Ltd. She combines a strong scientific background with extensive international business development experience. Passionate about building strategic partnerships and identifying new business opportunities, she is dedicated to advancing Energenesis’ global growth. Since joining the company in 2014, Shelly has led key initiatives in out-licensing drug candidates, conducting market assessments, and developing international distribution channels.

Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a Taiwan-based clinical-stage biopharmaceutical company developing innovative small-molecule therapeutics through its proprietary ENERGI-Platform. The platform is designed to enhance cellular ATP production and support intrinsic healing mechanisms, addressing significant unmet medical needs in chronic wounds, neurodegenerative diseases, and rare diseases. Through its subsidiary Repurgenesis, the company also expands its pipeline via AI-driven drug repurposing, identifying new therapeutic indications with reduced development risk, time, and cost.